Zhang 2013.

Methods	Study design: Randomised clinical trial Study duration: March 2009 to September 2011 Duration of follow‐up: 35 months Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by liver biopsy; tumour maximal diameter of 5‐10 cm; with liver function of Child‐Pugh Class A or B; unsuitable for resection or unwilling to accept surgery; with no history of treatments on HCC Age (mean ± SD): TACE + MWA: 52.1 ± 1.64 years; TACE alone: 55.57 ± 1.76 years Male (n/total): TACE + MWA: 48/60; TACE alone: 33/42 Tumour diameter (mean ± SD): TACE + MWA: 7.8 ± 1.37 cm; TACE: 7.34 ± 1.23 cm Child‐Pugh Class (patients): Class A: TACE + MWA: 42; TACE: 25 Class B: TACE + MWA: 18; TACE: 17
Interventions	TACE + MWA group (n = 60): TACE: Chemotherapeutic drugs: adriamycin 30‐50 mg. Multiple sessions of TACE were performed, with an interval of 3‐4 weeks. MWA: Output power of 50‐60 W; 10‐15 minutes per MWA session TACE group (n = 42): Chemotherapeutic drugs: adriamycin 30‐50 mg. Multiple sessions of TACE were performed, with an interval of 3‐4 weeks.
Outcomes	Serum level of AFP Tumour response, according to mRECIST criteria, measured at 2 months after treatment 1‐ and 2‐year survival rates Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.